Physician profile
Stephen D Hammond
NPI 1023123643
$5,666.91
in general payments reported to CMS, 2019-2025
30 companies · $1,944 in 2025
The $1,944 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $233 · 2021: $304 · 2022: $697 · 2023: $744 · 2024: $1,398 · 2025: $1,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,435 · Travel and Lodging: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,434.83 |
| Travel and Lodging | $651.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,981.19 | 2019-2025 | Clareon, Centurion, Argos |
| Johnson & Johnson Surgical Vision, INC. | $384.50 | 2019-2025 | Tecnis Simplicity |
| Apellis Pharmaceuticals, INC. | $264.19 | 2023-2025 | Syfovre |
| Abbvie INC. | $258.97 | 2022-2025 | |
| Sight Sciences, INC. | $178.63 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $167.45 | 2019-2022 | |
| Astellas Pharma US INC | $163.33 | 2025 | Izervay |
| Cumberland Pharmaceuticals, INC. | $137.27 | 2022 | |
| Biotissue Holdings INC. | $126.49 | 2022-2025 | |
| Dompe US, INC. | $125.00 | 2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $110.64 | 2023-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $100.46 | 2025 | Acthar |
| Bausch & Lomb Americas INC. | $100.41 | 2022-2025 | Vyzulta, Infuse, Miebo |
| New World Medical,INC. | $88.43 | 2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Aerie Pharmaceuticals, INC. | $73.76 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $69.44 | 2024-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $64.02 | 2022-2023 | |
| Shire North American Group INC | $41.09 | 2019 | |
| Kala Pharmaceuticals, INC. | $37.90 | 2019-2020 | |
| Ucb, INC. | $23.53 | 2025 | Rystiggo |
| Pacira Pharmaceuticals Incorporated | $21.74 | 2024 | Exparel |
| Rxsight INC | $19.46 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Omeros Corporation | $18.95 | 2020 | |
| Ani Pharmaceuticals, INC. | $17.55 | 2024 | Purified Cortrophin Gel |
| Harrow Eye, LLC | $17.36 | 2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.97 | 2020 | |
| Ivantis, INC | $15.27 | 2020 | |
| Horizon Therapeutics Plc | $15.22 | 2023 | Tepezza |
| Rayner Intraocular Lenses Limited | $14.51 | 2022 | |
| Oyster Point Pharma, INC. | $13.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hammond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.